Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

Recruiting

Conditions: Cancer Survivor
Biological Sibling
Retinoblastoma
Intraocular Retinoblastoma
Unilateral Retinoblastoma

Interventions: Procedure: Biospecimen collection
Other: Vision assessment
Other: Questionnaire administration
Other: Quality of life assessment
Other: Laboratory Biomarker Analysis

First Posted Date: 2019-05-01

Last Posted Date: 2024-11-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 900

Registration Number: NCT03932786

Locations: 🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
University of Illinois, Chicago, Chicago, Illinois, United States
🇺🇸
University of Minnesoa, Minneapolis, Minnesota, United States

and more 8 locations

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase 1

Terminated

Conditions: Ovarian Clear Cell Adenocarcinoma
Recurrent Endometrial Carcinoma
Fallopian Tube Carcinosarcoma
Fallopian Tube Endometrioid Adenocarcinoma
High Grade Fallopian Tube Serous Adenocarcinoma
High Grade Ovarian Serous Adenocarcinoma
Ovarian Carcinosarcoma
Primary Peritoneal Serous Adenocarcinoma
Fallopian Tube Cancer
Fallopian Tube Clear Cell Adenocarcinoma

Interventions: Drug: Entinostat
Drug: Olaparib

First Posted Date: 2019-04-23

Last Posted Date: 2022-04-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT03924245

Locations: 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents

Not Applicable

Completed

Conditions: Advanced Cancer
Relapsed Cancer
Refractory Cancer

Interventions: Behavioral: Animal-Assisted Interactions

First Posted Date: 2018-12-05

Last Posted Date: 2023-01-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 70

Registration Number: NCT03765099

Locations: 🇺🇸
Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee, United States

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Phase 2

Active, not recruiting

Conditions: Malignant Solid Tumor

Interventions: Other: Placebo
Drug: Ifetroban Sodium

First Posted Date: 2018-10-03

Last Posted Date: 2024-06-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT03694249

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1

Withdrawn

Conditions: Metastatic Squamous Cell Carcinoma of the Head or Neck
Squamous Cell Carcinoma
Recurrent Squamous Cell Carcinoma of the Head or Neck

Interventions: Drug: Nivolumab
Drug: Afatinib

First Posted Date: 2018-08-29

Last Posted Date: 2019-06-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT03652233

Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer

Not Applicable

Terminated

Conditions: Extensive Stage Small Cell Lung Carcinoma

Interventions: Procedure: Tumor Treating Fields (TTF) Therapy
Device: NovoTTF-200A Device
Other: Quality-of-Life Assessment

First Posted Date: 2018-07-31

Last Posted Date: 2020-08-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 2

Registration Number: NCT03607682

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Phase 1

Completed

Conditions: Thymic Carcinoma
Non-small Cell Lung Cancer
Refractory Thoracic Tumors
Small-Cell Lung Cancer

Interventions: Drug: Vorolanib
Biological: Nivolumab

First Posted Date: 2018-07-11

Last Posted Date: 2024-10-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 88

Registration Number: NCT03583086

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

and more 4 locations

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Phase 1

Terminated

Conditions: Stage III Breast Cancer
HER2/Neu Negative
Stage IV Breast Cancer
Estrogen Receptor-positive
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Cobimetinib
Drug: Idasanutlin

First Posted Date: 2018-06-25

Last Posted Date: 2021-08-11

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 12

Registration Number: NCT03566485

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Phase 1

Terminated

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Central Nervous System Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Central Nervous System Lymphoma

Interventions: Biological: Nivolumab
Biological: Rituximab
Drug: Lenalidomide

First Posted Date: 2018-06-15

Last Posted Date: 2019-04-25

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 6

Registration Number: NCT03558750

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

Recruiting

Conditions: Cancer
Diabetes Mellitus

Interventions: Drug: 2 OGTTs with and without GLP-1 analogue
Drug: Oral Glucose Tolerance Test (OGTT)
Drug: Hyperglycemic clamp procedure

First Posted Date: 2018-01-30

Last Posted Date: 2022-03-28

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 120

Registration Number: NCT03415139

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy